Infusion Laboratory: Protocol 1 - Selegeline - 2

National Institutes of Health (NIH)

Status and phase: Completed; Phase 1

Conditions: Cocaine-Related Disorders

Treatments: Drug: Selegiline

Study type: Interventional

Funder types: NIH

Identifiers

NCT00000337

NIDA-3-0010-2

Y01-3-0010-2

Details and patient eligibility

About

The purpose of this study is to determine the effects of selegiline on the subjective and physiological effects of cocaine challenge in chronic crack abusers, and to evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.

Full description

To develop a medication for the treatment of cocaine addiction using a medical human physio-neuro-psycho-immunology laboratory setting. To characterize this cocaine abusing population on a variety of psychological and physicologically measures over time from withdrawal through pere and post cocaine administration. To determine the effects of selegeline on the subjective and physiological effects of cocaine challenge in chronic crack abusers. To evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.

Sex: All

Ages: 31 to 47 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion criteria

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.